Navigation Links
Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
Date:11/16/2009

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will webcast its annual meeting with institutional investors and financial analysts in New York on Thursday, December 3, 2009, at 9 a.m. Eastern Time (ET). The event will feature presentations on Gen-Probe's current business and future growth strategies by several Company executives. The meeting and webcast will conclude at noon ET.

The meeting will be webcast live and may be accessed on the investors section of the Company's web site at www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 30 days.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Contact:
    Paula Izidoro
    Investor Relations
    858-410-8904

SOURCE Gen-Probe Incorporated


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
2. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
3. Gen-Probe to Webcast Four Upcoming Investor Presentations
4. Gen-Probe to Webcast Two Upcoming Investor Presentations
5. Gen-Probe Completes Acquisition of Tepnel Life Sciences
6. Gen-Probe to Webcast Two Upcoming Investor Presentations
7. Gen-Probe Borrows $170 Million Under New Line of Credit
8. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
9. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
10. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
11. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):